Coherus BioSciences (CHRS)

CHRS Biosimilars

BiotechSign Signal Grade

F
Signal Grade
14.9/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Publications
100
Dilution Risk
71
Clinical Activity
0
Short Interest
50

Pipeline Overview

Therapeutic Focus
Biosimilarssrc

Clinical Trial Activity

0
Clinical Trials
(ClinicalTrials.gov aggregate)
5
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov

Dilution Risk

HIGH DILUTION RISK
6.3 months
Cash Runway Estimate
71/100
Dilution Score
40Warrant Risk
85Convertible Risk
62Offering Ability

Dilution score: 71/100 (HIGH), 6.3 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

17.24%
Float Shorted
32.8
Days to Cover
MODERATE
Squeeze Risk
-4.5%
SI Change
STABLE
Trend
22,848,985
Shares Short

Short interest: 17.24% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Coherus BioSciences.

Full CHRS Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.